Pointers PE invests ₩15B in ReMed…"growth opportunity in global neurotech"
Predicted impact: Medium
₩15B investment and share cancellation of ₩1.9B; convertible bond amendment noted.
Remed리메드
302550 · KOSDAQ · ₩302550 · 리메드
₩2,215▼ ₩80 (3.49%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −32.88%
- Market cap
- ₩67B
- Enterprise value
- ₩60B
- P/E
- 32.7×
- P/B
- 1.8×
- Dividend yield
- 0.0%
- ROE
- 5.4%
- Net margin
- 7.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−45.6% from the high
₩2,045Today: ₩2,195 – ₩2,295₩4,070
Returns
- 1W−2.6%
- 1M−16.7%
- 3M−10.9%
- 6M−28.2%
- YTD−27.9%
- 1Y−32.9%
- Volume today
- 71,870
- 0.1× the 20-day average
- Traded today
- ₩159M
- Listed shares
- 30,275,013
- EPS (12 months)
- ₩68
- Earnings yield 3.1%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 25 of 100 (50 is a normal day for this stock).
- MomentumWeak-15.1% over the last month; the price is below its 20-day average.
- News impactSome7 news items and filings in two weeks; 0 rated high impact, 4 medium.
Signals describe activity, not recommendations. Not financial advice.
Remed stock overview
Remed (리메드, KRX: 302550) is listed on KOSDAQ, in the Medical & precision devices sector. The company develops and manufactures medical devices that use strong magnetic fields or electrical stimulation to treat and rehabilitate various conditions through non-invasive stimulation. Its shares closed at ₩2,215 on Oct 29, 2026, down 3.49% on the day, giving it a market value of ₩67B.
Key facts
- Market cap
- ₩67B
- Sector
- Medical & precision devices
- Latest price change
- −3.49%
- As of
- Oct 29, 2026
- Main business
- The company develops and manufactures medical devices that use strong magnetic fields or electrical stimulation to treat and rehabilitate various conditions through non-invasive stimulation.
Quick answers about Remed
- What does Remed do?
- The company develops and manufactures medical devices that use strong magnetic fields or electrical stimulation to treat and rehabilitate various conditions through non-invasive stimulation. Its main businesses are brain rehabilitation using transcranial magnetic stimulation (TMS) products such as BrainStim and ALTMS, mainly for depression, chronic pain treatment using Neuro Magnetic Stimulation (NMS) products such as the Salus Talent Series and emField Pro, and aesthetic products for core muscle strengthening such as ZTone, along with focused shockwave therapy devices such as Salus FSWT. Its products are sold in Korea and many overseas markets, including China, Japan, Europe, and the United States.
- What is the market cap of Remed?
- The market capitalisation of Remed was ₩67B at the close on Oct 29, 2026.
- Who are the largest shareholders of Remed?
- According to the latest official filings, the largest reported holders are Lee Geun-yong (36.88%, as of Oct 20, 2026); Samsung Innovative New Technology Investment Partnership No. 1 (4.75%, as of Sep 3, 2025); National Pension Service (1.97%, as of Dec 31, 2021).
- When is the next earnings report from Remed?
- Korean companies rarely announce results dates in advance. Based on when Remed filed the same report in past years, its next 3q results is expected between Nov 12, 2026 and Nov 14, 2026.
- Does the National Pension Service own Remed?
- Yes. The National Pension Service held 1.97% of Remed shares as of Dec 31, 2021.
Company profile
The company develops and manufactures medical devices that use strong magnetic fields or electrical stimulation to treat and rehabilitate various conditions through non-invasive stimulation. Its main businesses are brain rehabilitation using transcranial magnetic stimulation (TMS) products such as BrainStim and ALTMS, mainly for depression, chronic pain treatment using Neuro Magnetic Stimulation (NMS) products such as the Salus Talent Series and emField Pro, and aesthetic products for core muscle strengthening such as ZTone, along with focused shockwave therapy devices such as Salus FSWT. Its products are sold in Korea and many overseas markets, including China, Japan, Europe, and the United States.
Written by AI from the company's latest annual report.
- Korean name
- 리메드
- Themes
- Medical devices
- CEO
- 이근용
- Founded
- Jul 2003
- Listed
- Dec 2019
- Listed shares
- 30,275,013
- Fiscal year ends
- Month 12
- Website
- remed.kr
Similar companies
- TSE131290 · ₩2.9T₩260,500−5.27%
- Kctech281820 · ₩1.9T₩97,500+2.09%
- Classys214150 · ₩1.7T₩26,800−0.74%
- Park Systems140860 · ₩1.6T₩228,500−0.44%
- DI003160 · ₩1.2T₩43,500+0.46%
- Curiox Biosystems445680 · ₩1T₩60,600−2.88%
- LivsMed491000 · ₩1T₩40,450−7.33%
- Seers458870 · ₩907B₩23,650−3.86%
Recent news
Pointers PE invests ₩15B in REMED, expanding into pain management and obesity treatment market
Predicted impact: Medium
Convertible bond worth about 20% of market value, but LF Investment's ₩15B deal was already reported.
Rimed to Cancel Shares Worth ₩1.9B… "Enhancing Shareholder Value"
Predicted impact: Medium
Share cancellation of about ₩1.9B is roughly 2.6% of market value, but tied to the same CB decision.
Recent filings
See all- Amended: Convertible bond issue decisionOct 27, 2026
- 5%+ holding reportOct 20, 2026
- Share cancellation decisionOct 19, 2026
- Amended: Convertible bond issue decisionOct 19, 2026
- Trading Plan Report for Executives and Major Shareholders' Specific SecuritiesOct 14, 2026
Titles in Korean until English translations are added.
Also known as: Remed / 리메드 / 302550 / KRX:302550
Source: KRX statistical information